ATE353632T1 - Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung - Google Patents
Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzungInfo
- Publication number
- ATE353632T1 ATE353632T1 AT03724207T AT03724207T ATE353632T1 AT E353632 T1 ATE353632 T1 AT E353632T1 AT 03724207 T AT03724207 T AT 03724207T AT 03724207 T AT03724207 T AT 03724207T AT E353632 T1 ATE353632 T1 AT E353632T1
- Authority
- AT
- Austria
- Prior art keywords
- sustained release
- estradiol metabolites
- compositions
- present
- hydroxyestradiol
- Prior art date
Links
- 150000002159 estradiols Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 238000013268 sustained release Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- DILDHNKDVHLEQB-XSSYPUMDSA-N 2-hydroxy-17beta-estradiol Chemical compound OC1=C(O)C=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 DILDHNKDVHLEQB-XSSYPUMDSA-N 0.000 abstract 1
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 abstract 1
- QOZFCKXEVSGWGS-ZHIYBZGJSA-N 4-hydroxy-17beta-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1O QOZFCKXEVSGWGS-ZHIYBZGJSA-N 0.000 abstract 1
- BCWZIZLVBYHFES-PYEWSWHRSA-N 4-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=CC(O)=C1OC BCWZIZLVBYHFES-PYEWSWHRSA-N 0.000 abstract 1
- 241000272173 Calidris Species 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- 239000010408 film Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 239000000017 hydrogel Substances 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 239000007937 lozenge Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003094 microcapsule Substances 0.000 abstract 1
- 239000011859 microparticle Substances 0.000 abstract 1
- 239000002088 nanocapsule Substances 0.000 abstract 1
- 239000002105 nanoparticle Substances 0.000 abstract 1
- -1 patches Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 239000006213 vaginal ring Substances 0.000 abstract 1
- 235000012431 wafers Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37749002P | 2002-05-03 | 2002-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE353632T1 true ATE353632T1 (de) | 2007-03-15 |
Family
ID=29401508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03724207T ATE353632T1 (de) | 2002-05-03 | 2003-04-25 | Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060083778A1 (https=) |
| EP (1) | EP1507514B1 (https=) |
| JP (1) | JP2005525403A (https=) |
| AT (1) | ATE353632T1 (https=) |
| AU (1) | AU2003231082A1 (https=) |
| DE (1) | DE60311801T2 (https=) |
| WO (1) | WO2003092585A2 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040157816A1 (en) * | 2002-08-26 | 2004-08-12 | Girouard Michael P. | Monounsaturated fatty acids and perhydrocyclopentanophenanthrene nucleus combination molecules, and their precursors, and the use of all of these as weight-loss agents |
| EP1829529A1 (en) * | 2002-05-03 | 2007-09-05 | PR Pharmaceuticals, Inc. | Controlled release compositions of estradiol metabolites |
| US20040082558A1 (en) * | 2002-08-02 | 2004-04-29 | Tofovic Stevan P. | Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| EP2548550A1 (en) | 2003-04-10 | 2013-01-23 | Surmodics Pharmaceuticals, Inc. | Emulsion-based micro particles |
| JP5165239B2 (ja) | 2003-07-15 | 2013-03-21 | ピーアール ファーマシューティカルズ， インコーポレイテッド | 制御放出処方物の調製のための方法 |
| WO2005009357A2 (en) | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| WO2006088647A1 (en) * | 2005-02-17 | 2006-08-24 | Medivas, Llc | Polymer particle delivery compositions and methods of use |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20060057216A1 (en) * | 2004-09-15 | 2006-03-16 | Salamone Joseph C | Low-obscuration image transmitting particulate ocular therapeutic formulations |
| US20090280064A1 (en) * | 2005-06-24 | 2009-11-12 | Rao Papineni | Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans |
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| SG10201607909WA (en) | 2006-12-01 | 2016-11-29 | Anterios Inc | Peptide nanoparticles and uses therefor |
| WO2008070538A2 (en) | 2006-12-01 | 2008-06-12 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| JP4849647B2 (ja) * | 2007-09-10 | 2012-01-11 | エム・テクニック株式会社 | 生体摂取物の製造方法及びこれにより得られた生体摂取物 |
| US20120015017A1 (en) * | 2009-05-19 | 2012-01-19 | Nyden Bo Magnus | Slow releasing microcapsules containing an active substance |
| US20110275686A1 (en) * | 2009-12-11 | 2011-11-10 | Biolitec, Inc. | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
| CN101953774B (zh) * | 2010-09-17 | 2011-11-23 | 郑州大学 | 2-甲氧基雌二醇可注射水凝胶植入剂 |
| US8580294B2 (en) | 2010-10-19 | 2013-11-12 | International Partnership For Microbicides | Platinum-catalyzed intravaginal rings |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| KR102005579B1 (ko) * | 2012-11-19 | 2019-07-30 | 가톨릭대학교 산학협력단 | 세포배양용 다공성 지지체 및 이의 제조방법 |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| WO2014164723A1 (en) * | 2013-03-12 | 2014-10-09 | The Johns Hopkins University | Short-chain fatty acid hexosamine analogs and their use in tissue engineering applications |
| GB2521334B (en) * | 2013-08-21 | 2018-06-20 | Univ Swansea | Topical drug patch including microspheres |
| US10137031B2 (en) | 2013-11-14 | 2018-11-27 | International Partnership For Microbicides, Inc. | Combination therapy intravaginal rings |
| CL2013003807A1 (es) * | 2013-12-31 | 2014-07-11 | Univ Santiago Chile | Dispositivos de tubos pequeños de silicona que contienen nanopartículas y micropartículas de zeolitas como agentes de liberación prolongada y controlada, cargadas con 2-metoxiestradiol y suspendidas en un medio oleoso que también contiene 2-metoxiestradiol. |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| WO2016156403A1 (en) * | 2015-03-31 | 2016-10-06 | Merck Sharp & Dohme B.V. | Vaginal ring applicator |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| AU2017360346B2 (en) | 2016-11-21 | 2023-11-23 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| JP7296520B2 (ja) * | 2019-03-19 | 2023-06-22 | 株式会社リーゼンバイオテク | ステロイド系薬物を含む生分解性高分子微細粒子及びその製造方法 |
| CN113509448A (zh) * | 2020-07-02 | 2021-10-19 | 安徽中医药大学 | 一种可生物降解控释长效植入片及其制备方法 |
| CN116059181A (zh) * | 2022-09-26 | 2023-05-05 | 上海交通大学医学院附属新华医院 | 一种纳米药物递送系统 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288496A (en) * | 1990-05-15 | 1994-02-22 | Stolle Research & Development Corporation | Growth promoters for animals |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5686092A (en) * | 1992-11-24 | 1997-11-11 | Alkermes Controlled Therapeutics Inc. Ii | Growth promoters for animals |
| NZ311474A (en) * | 1995-06-09 | 1997-09-22 | Euro Celtique Sa | Formulations for providing prolonged local anesthesia |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6495579B1 (en) * | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
| AU7134898A (en) * | 1997-04-17 | 1998-11-11 | Amgen, Inc. | Biodegradable microparticles for the sustained delivery of therapeutic drugs |
| AUPQ342599A0 (en) * | 1999-10-14 | 1999-11-04 | University Of Melbourne, The | Conjugates and uses thereof |
| US6743446B2 (en) * | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
| US6998395B2 (en) * | 2001-08-17 | 2006-02-14 | University Of Pittsburg, | Administration of estradiol metabolites for the treatment or prevention of obesity, metabolic syndrome, diabetes, and vascular and renal disorders |
-
2003
- 2003-04-25 US US10/513,542 patent/US20060083778A1/en not_active Abandoned
- 2003-04-25 AU AU2003231082A patent/AU2003231082A1/en not_active Abandoned
- 2003-04-25 DE DE60311801T patent/DE60311801T2/de not_active Expired - Fee Related
- 2003-04-25 EP EP03724207A patent/EP1507514B1/en not_active Expired - Lifetime
- 2003-04-25 AT AT03724207T patent/ATE353632T1/de not_active IP Right Cessation
- 2003-04-25 JP JP2004500770A patent/JP2005525403A/ja active Pending
- 2003-04-25 WO PCT/US2003/012727 patent/WO2003092585A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003231082A8 (en) | 2003-11-17 |
| AU2003231082A1 (en) | 2003-11-17 |
| EP1507514A4 (en) | 2005-08-10 |
| DE60311801T2 (de) | 2007-11-08 |
| EP1507514B1 (en) | 2007-02-14 |
| US20060083778A1 (en) | 2006-04-20 |
| EP1507514A2 (en) | 2005-02-23 |
| WO2003092585A3 (en) | 2004-08-19 |
| DE60311801D1 (de) | 2007-03-29 |
| JP2005525403A (ja) | 2005-08-25 |
| WO2003092585A2 (en) | 2003-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE353632T1 (de) | Zusammensetzungen aus östradiol-metaboliten mit kontrollierter freisetzung | |
| Herculano et al. | On the release of metronidazole from natural rubber latex membranes | |
| Ji et al. | An esterase-activated click and release approach to metal-free CO-prodrugs | |
| ES2249197T1 (es) | Formulaciones de adhesivo de silicona con base de suspension de fentanilo y dispositivos para la administracion transdermica de fentanilo. | |
| US11304950B2 (en) | Methods for treating testicular and ovarian adrenal rest tumors | |
| DK0831787T3 (da) | Sammensætning til vedvarende frigivelse af humant væksthormon | |
| ES2422655T3 (es) | Formulaciones de liberación inmediata potenciadas de topiramato | |
| DK1768625T3 (da) | Sammensætninger med vedvarende frigørelse indeholdende progesteron-receptormodulatorer | |
| BRPI0407485A (pt) | utilização de anticorpos anti-receptores de factor crescimento i semelhantes aos anti-insulina | |
| AR049985A1 (es) | Tratamiento de combinacion para enfermedades malignas no hematologicas | |
| ATE472551T1 (de) | Tocopherolmodifizierte therapeutische arzneimittelverbindung | |
| PE20130524A1 (es) | Forma farmaceutica parenteral, que libera inhibidores de aromatasa y gestagenos para el tratamiento de endometrosis | |
| JP2010520888A (ja) | 神経変性の治療としてのニトロキシドラジカル | |
| CN114650809A (zh) | 屈大麻酚的透皮递送 | |
| AU2014352920A1 (en) | Novel methods for treating neurodegenerative diseases | |
| JP2022507102A (ja) | イブプロフェンまたはその構造類似体を含む多層経皮薬物送達システム | |
| JP2008521904A (ja) | 置換ベンゾオキサゾールの製剤 | |
| EP1494646A1 (en) | Intravaginal matrix drug delivery devices | |
| AR040287A1 (es) | Plataforma para formulaciones transdermicas (pft) | |
| TR200301553A1 (tr) | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar | |
| NO20063805L (no) | Hoyrent butokonazolnitrat med spesifisert partikkelstorrelse og en fremgangsmate for fremstilling derav | |
| ECSP056190A (es) | Compuestos utiles en la terapia de la enfermedad de alzheimer y formulaciones que los contienen | |
| TWI576245B (zh) | 具抑制結晶保護膜（離型襯墊）之經皮治療系統 | |
| WO2011150239A2 (en) | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith | |
| JP2001187739A (ja) | アレルギー性皮膚疾患治療用外用剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |